Denosumab: a new option in the treatment of bone metastases from urological cancers

@inproceedings{Yuasa2012DenosumabAN,
  title={Denosumab: a new option in the treatment of bone metastases from urological cancers},
  author={Takeshi Yuasa and Shinya Yamamoto and Shinji Urakami and Iwao Fukui and Junji Yonese},
  booktitle={OncoTargets and therapy},
  year={2012}
}
BONE METASTASES OFTEN CREATE SERIOUS CLINICAL PROBLEMS: they lead to poor performance status due to pathologic fractures, spinal cord compression and intractable pain, commonly referred to as skeletal-related events. The receptor activator of nuclear factor-κB (RANK), the RANK ligand (RANKL), and osteoprotegerin, a decoy receptor for RANK, regulate osteoclastogenesis and may play a key role in bone metastasis. Denosumab (XGEVA; Amgen, Thousand Oaks, CA), a fully human monoclonal antibody that… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Treatment outcome and prognostic factors of the patients with renal cell cancer bone metastasis

T Yuasa, S Urakami, S Yamamoto
  • Clin Exp Metastasis
  • 2011
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgendeprivation therapy for prostate cancer

MR Smith, B Egerdie, N Hernández Toriz
  • N Engl J Med
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL